Genmab AS

Genmab AS Financing Cash Flow

The Net Financing Cash Flow of Genmab AS (GMAB) as of Nov 22, 2026 is 4.79 B USD. In the previous year, Net Financing Cash Flow was -3.92 B USD — a change of -222.30% (higher).

Financing Cash Flow

4.79 BUSD

YoY

-222.30%

Last updated:

Net Financing Cash Flow of Genmab AS is 2025 4.79 B USD. Net Financing Cash Flow of Genmab AS was 2024 -3.92 B USD. It decreases by -222.30% higher compared to the previous year.

The Genmab AS Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
-70.90 M USD
Jan 1, 2019
3.66 B USD
Jan 1, 2020
71.00 M USD
Jan 1, 2021
-420.00 M USD
Jan 1, 2022
-789.00 M USD
Jan 1, 2023
-606.00 M USD
Jan 1, 2024
-3.92 B USD
Jan 1, 2025
4.79 B USD
The Genmab AS Financing Cash Flow history
YEARFinancing Cash FlowYoY
4.79 BUSD-222.30%
-3.92 BUSD+546.70%
-606.00 MUSD-23.19%
-789.00 MUSD+87.86%
-420.00 MUSD-691.55%
71.00 MUSD-98.06%
3.66 BUSD-5,262.13%
-70.90 MUSD-132.99%
214.91 MUSD+135.68%
91.19 MUSD-85.82%
643.09 MUSD-37.89%
1.04 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

Net Financing Cash Flow of Genmab AS is 4.79 B USD in 2025.

Net Financing Cash Flow of Genmab AS changed from -3.92 B USD to 4.79 B USD, representing a -222.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Genmab AS since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Genmab AS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genmab AS

All Key Metrics — Genmab AS